TP53 and cancer: Although we were able to confirm the silencing of only Δ160p53α, interestingly, the rate of cell viability was slightly but significantly reduced when combining Δ160p53α down-regulation with cisplatin and proton beam administration, indicating that reduced levels of at least this p53 variant make the UM cells more responsive and sensitive to anti-cancer treatments (Fig. 5B) (Fig. 6B, panel 1).